SAN DIEGO(BUSINESS WIRE)
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the Company) (OTCQB
Venture Market: INNV), an emerging over-the-counter (OTC) consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men's
and women's health and vitality and respiratory diseases, announced
today the signing of an exclusive license and distribution agreement
with Densmore Pharmaceutical International (Densmore), a company based
in Monaco for the commercialization of Zestra in France and Belgium.
We are pleased to expand the commercialization market for Zestra in
the European Union to France and Belgium, said Innovus Pharma CEO, Dr.
Bassam Damaj. Densmore is our 15th distribution partner for
our products outside the United States and is very important for us to
compete in one of the largest markets in Europe said Innovus CEO Dr.
Bassam Damaj. This partnership is one more step towards achieving our
2017 corporate goals for revenue and profitability from our
international distributors, continued Dr. Damaj.
We are excited to commercialize Zestra for the French and the Belgium
market as it will fulfill a large unmet medical need. Zestra is a very
well-studied project with strong placebo controlled clinical trials and
we believe it will provide a strong natural solution for women, said
Dr. Philippe Caron CEO of Densmore, and an authority on women's health
products in the French market.
Zestra is currently exclusively partnered with Orimed Pharma, the OTC
subsidiary of Jamp Pharma in Canada, DanaLife ApS in select European
markets, Sothema Laboratories for the Middle East and North Africa, Elis
Pharmaceuticals in Turkey and certain select markets, Oz Biogenics for
Myanmar and Vietnam, BioTask in Malaysia and J&H Co. LTD in South Korea,
and non-exclusively to PT Resources in Hong Kong and certain select
Zestra is approved in Canada, the 28 countries of the European Union,
India, Hong Kong, the United Arab Emirates (UAE), United Kingdom and
Morocco. Innovus currently generates revenues from the following markets
for Zestra: Canada, Morocco, certain European countries and Hong Kong
in addition to the United States as its biggest market.
About Zestra and FSI/AD
Zestra is a patented blend of natural oils clinically-proven in
double-blind placebo-controlled clinical trials in 276 women to increase
in a statistical significant manner the arousal, desire and sexual
satisfaction in FSI/AD women. To the Company's knowledge, Zestra is the
first NHP product to receive approval for the indication of FSI/AD in
Canada. To date, no product has been approved to treat FSI/AD, a
persistent or recurring inability to attain or maintain adequate sexual
excitement until the completion of a sexual activity. The diagnosis can
also refer to an inadequate lubrication-swelling response normally
present during arousal and sexual activity causing personal distress.
Published papers on the FSI/AD market size estimate it to be equal or
larger than the market for erectile dysfunction in males, and possibly
Approximately 43% of women in the United States age 18 to 59, or ~50
million, experience some form of Female Sexual Dysfunction (FSD)
according to a published study. (Laumann, E.O. et al. Sexual Dysfunction
in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999.
vol. 281, No. 6.537-542) and (http://www.indexmundi.com/south-korea/demographics-profile.html).
The FSD market in the United States is estimated to be more than $1
billion per year. For more information on Zestra visit www.zestra.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (OTC) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men's and women's health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists and therapists, and
(c) directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(ANDA) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com,
About Densmore Pharmaceutical International
Densmore is based in Monaco and has been in operation since 1946. Its
research and development center has about 70 years of expertise in
vitamin therapy and micro-nutrition formulas. Since the early 2000's,
Densmore has acquired new skills in drugs, medical devices and
cosmetics. It received two innovations and research awards for the
entire range. In addition to its presence in France, Densmore is
exported to many countries in Europe and north Africa. Densmore's aim is
to make available to all, the medical professions and patients,
innovative products that combine safety, security and easy to use to
meet the health needs and well-being in everyday life. See www.densmore.mc.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, to successfully
commercialize Zestra and other products in France, Belgium and in other
countries in the European Union, the U.S. and internationally and to
achieve its other development, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, and other filings made with the SEC. Copies of
these reports are available from the SEC's website or without charge
from the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170516005446/en/
Emerging Markets Consulting, LLC
James S. Painter III, 321-206-6681
Source: Innovus Pharmaceuticals, Inc.